Microbio Co., Ltd. (TPEX: 4128)
Consumer Staples · Personal Care Products · TW
NT$15.30
+3.03% today · -32.3% 1Y
Microbio Co., Ltd. (TPEX: 4128) operates in the Personal Care Products industry within the Consumer Staples sector. The company is valued at $282.50M and employs 577 people.
Over the last twelve months the share price has lost 32.3%, trading between 13.60 and 23.05.
Tweenvest scores Microbio Co., Ltd. across four factors: quality 55/100, value 58/100, growth 35/100. Its strongest factor is value.
4128 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $282.50M
- Revenue (TTM)
- $61.78M
- P/E
- 17.20
- EPS
- 0.89
- Dividend yield
- —
- Beta (5Y)
- 0.49
- 52-week high
- NT$23.05
- 52-week low
- NT$13.60
- Avg volume (3M)
- —
- Shares outstanding
- 588.17M
- Employees
- 577
- Next earnings
- —
About Microbio Co., Ltd.
Microbio Co., Ltd., established in 2000 and headquartered in Taipei, Taiwan, functions as a comprehensive biotechnology enterprise. The company's core activities involve the research, development, manufacturing, and commercialization of advanced biopharmaceutical drugs and nutritional supplements within Taiwan. Currently, Microbio offers two key products: MS-20, designed to alleviate fatigue and appetite loss experienced by cancer patients undergoing chemotherapy, and Herbiron, aimed at addressing symptoms linked to iron deficiency anemia and menstrual discomfort. Its robust drug pipeline includes several compounds in various stages of development. In the preclinical phase, the company is developing SNA-03 and SNA-07 for cancer immunotherapy, SNP-630 for non-alcoholic steatohepatitis (NASH), FB918 targeting non-allergic eosinophilic asthma, and SNS812 as an investigational treatment for Cov-flu. Moving into Phase I clinical trials, Microbio is advancing OB-318 as an anti-cancer agent, MB-110 for hepatitis C therapy, SNP-810 as an acetaminophen alternative, FB317 for moderate-to-severe allergic asthma and chronic idiopathic urticaria, and FB704A, which is being explored for conditions like rheumatoid arthritis, certain cancers, and cytokine storms. Furthermore, FB825 is currently undergoing Phase II clinical assessment for its potential in treating atopic dermatitis, allergic asthma, hyper IgE syndrome, and various food allergies. In its late-stage development, Microbio has two products in Phase III trials: ON101, designed to treat diabetic foot ulcers, and MB-6, an adjuvant therapy for metastatic colorectal cancer. The discovery pipeline holds additional candidates such as FB121 for AIDS, SNA01 for PD-1 related cancers, SNA02 for cancer immunotherapy, and SNS01 targeting recurrent metastatic non-small cell lung cancer. Additionally, Microbio is developing SNP-830 and SNP-840, novel analgesics designed to be free from hepatotoxicity. Beyond pharmaceuticals, Microbio diversifies its operations through organic food trading, beverage sales, technology development and transfer services, consulting, and even magazine publishing.
- ISIN
- TW0004128004
- Founded
- 2000
- Listed since
- Dec 31, 2007
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Personal Care Products companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Henan Rebecca Hair Products Co., Ltd.SHSE: 600439 | $310.51M | CN¥1.84 | -1.08% |
| Euglena Co., Ltd.TSE: 2931 | $294.53M | ¥333.00 | -5.13% |
| Haleon Pakistan LimitedKASE: HALEON | $289.62M | PKRs685.10 | +0.16% |
| BioForce Nanosciences Holdings, Inc.OTCPK: BFNH | $287.40M | $7.55 | -19.23% |
| USANA Health Sciences, Inc.NYSE: USNA | $270.87M | $14.66 | 0.00% |
| Ya-Man Ltd.TSE: 6630 | $268.96M | ¥771.00 | -1.28% |
| NeoPharm CO., LTD.KOSDAQ: A092730 | $268.28M | ₩23,100.00 | -2.33% |
| Shinnihonseiyaku Co., Ltd.TSE: 4931 | $263.79M | ¥1,964.00 | -4.89% |
Figures last refreshed Oct 4, 2026.